bioRxiv · 10.1101/2025.03.31.646453
Crystallographic fragment screening of the dengue virus polymerase reveals multiple binding sites for the development of non-nucleoside antiflavivirals
Abstract
Dengue viruses (DENV) infect approximately 400 million people each year, and there are currently no effective therapeutics available. To explore potential starting points for antiviral drug development, we conducted a large-scale crystallographic fragment screen targeting the RNA-dependent RNA polymerase (RdRp) domain of the non-structural protein 5 (NS5) from DENV serotype 2. Our screening, which involved 1,108 fragments, identified 60 hit compounds across various known binding sites, including the active site, N pocket, and RNA tunnel. Additionally, we discovered a novel binding site and a fragment-binding hotspot in thumb site II. These structural findings open amenable avenues for developing non-nucleoside inhibitors and offer valuable insights for future structure-based drug design aimed at DENV and other flaviviral RdRps.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Saini, M., Aschenbrenner, J. C., Ruiz, F. X., Chopra, A., Chandran, A. V., Marples, P. G., Balcomb, B. H., Fearon, D., von Delft, F., Arnold, E.. 2025-04-05. Crystallographic fragment screening of the dengue virus polymerase reveals multiple binding sites for the development of non-nucleoside antiflavivirals. https://doi.org/10.1101/2025.03.31.646453
Cite the original work for its findings. Save a collection to share your selection of sources.